David Lebowitz

GW Pharma Analysts Raise Estimates After CBD Drug Epidiolex Shows Strong Uptake

Ionis Wins Price Target Hike On Partner Biogen's Guidan

Morgan Stanley: DEA Likely To Reclassify GW Pharma's Cannabinoid Therapy For US Launch

Ionis Wins Price Target Hike On Partner Biogen's Guidan

Morgan Stanley: DEA Likely To Reclassify GW Pharma's Cannabinoid Therapy For US Launch

Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate

Newly Public Gene Therapy Biotech Avrobio Picks Up Two Sell-Side Bulls

Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate

Newly Public Gene Therapy Biotech Avrobio Picks Up Two Sell-Side Bulls

Unity Biotech Is A Buy On 'Novel Biology,' Morgan Stanley Says In Positive Initiation

Morgan Stanley Turns Bearish On Ironwood Pharma, Lowers Linzess Sales Estimate

David Lebowitz Recent News

Insmed Has $700M Opportunity With Lung Disease Treatment, Says Morgan Stanley

Morgan Stanley Gets Wise On Sage Therapeutics, Initiates With A Buy

As Celgene Outperforms, Are Challenges To Its Pipeline Being Overlooked?

Sarepta's Upside Story Is Just Getting Started

Data Monitoring Committee Determines Alnylam's ENDEAVOUR Trial May Continue

Raptor Pharmaceuticals Buys Quinsair: What You Need To Know